DongKoo Bio & Pharma Co Ltd (006620)

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs. It offers cosmetic products under the CELL BLOOM brand; MediBloom MD Lotion/Cream for wound treatment; and medical devices for skin therapy, aesthetic, scalp care, and skin diagnosis. In addition, the company develops DKB15003 for dyslipidemia; DKB17001 for BPH/OAB; DKB17002 for Lumbago; DKB19001 for hypertension/dyslipidemia; DKB19002, DKB20001, DKB20002, DKB20004, DKB1903, DKB1903C, and DKB2001 for diabetes; DKB19003 for allergic rhinitis; DKB20003 for venous lymphatic insufficiency; NCP112 for atopic dermatitis; DKB1904 for allergy/dermatitis; DKB1801 for acne; and DKB1902 and DKB2014 for psoriasis. Further, it engages in new technology, financial, pharmaceutical marketing, and agency businesses. The company was formerly known as DongKoo Pharm Co., Ltd. and changed its name to DongKoo Bio & Pharma Co., Ltd. in January 2014. The company was founded in 1970 and is headquartered in Seoul, South Korea.